Liminatus Pharma IncLIMN
Price$3.75

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 30 Jun 2026
Net Income -$12.5MTTM through 30 Jun 2026
Free Cash Flow -$4MTTM through 30 Jun 2026

Margins

Current

Balance Sheet Health

Debt / Equity-10.88x
Current Ratio0.05x
Net Debt-$470Knet cash position
Cash & Equivalents$1.9M

Quality Metrics

Altman Z-Score-19.79
Piotroski F-Score3 / 9

Multi-Year Trend

Diluted EPS-$0.48TTM
'24'25
FY2025: $-0.43

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Immuno-oncology Therapeutics$0
View details

Planning to initiate Phase 1 clinical trials for IBA101 in early 2027.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.